In the last trading session, 1.61 million uniQure N.V (NASDAQ:QURE) shares changed hands as the company’s beta touched 0.04. With the company’s per share price at $13.70 changed hands at $0.45 or 3.40% during last session, the market valuation stood at $750.05M. QURE’s last price was a discount, traded about -40.0% off its 52-week high of $19.18. The share price had its 52-week low at $3.73, which suggests the last value was 72.77% up since then.
Analysts gave the uniQure N.V (QURE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended QURE as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
uniQure N.V (NASDAQ:QURE) trade information
Instantly QURE was in green as seen at the end of in last trading. With action 7.11%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -22.42%, with the 5-day performance at 7.11% in the green. However, in the 30-day time frame, uniQure N.V (NASDAQ:QURE) is 45.90% up.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 49.26% from its current market value. According to analyst projections, QURE’s forecast low is 24 with 30 as the target high. To hit the forecast high, the stock’s price needs a -118.98% plunge from its current level, while the stock would need to soar -75.18% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.66%. The 2025 estimates are for uniQure N.V earnings to increase by 29.11%, but the outlook for the next 5-year period is at 37.73% per year.
QURE Dividends
uniQure N.V is expected to release its next quarterly earnings report in June.
NANTAHALA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 5.4511% or 2.65 million shares worth $11.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and abrdn Healthcare Investors . With 987.12 shares estimated at $13.52 million under it, the former controlled 1.80% of total outstanding shares. On the other hand, abrdn Healthcare Investors held about 1.48% of the shares, roughly 812.69 shares worth around $11.13 million.
